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OBJECTIVE: Hypoxia-inducible factor 1 alpha regulates genes related to cellular survival under hypoxia. This factor is
present in osteroarthritic chondrocytes, and cytokines, such as interleukin-1 beta, participate in the pathogenesis of
osteoarthritis, thereby increasing the activities of proteolytic enzymes, such as matrix metalloproteinases, and
accelerating cartilage destruction. We hypothesize that Hypoxia Inducible Factor-1 alpha (HIF-1a) can regulate
cytokines (catabolic action) and/or growth factors (anabolic action) in osteoarthritis. The purpose of this study was
to investigate the modulation of HIF-1a in human osteoarthritic chondrocytes by interleukin-1 beta (IL-1b) and
insulin-like growth factors I (IGF-I) and II (IGF-II) and to determine the involvement of the phosphatidylinositol-3-
kinase (PI-3K) pathway in this process.
METHODS: Human osteroarthritic chondrocytes were stimulated with IL-1b, IGF-I and IGF-II and LY294002, a specific
inhibitor of PI-3K. Nuclear protein levels and gene expression were analyzed by western blot and quantitative
reverse transcription-polymerase chain reaction analyses, respectively.
RESULTS: HIF-1a expression was upregulated by IL-1b at the protein level but not at the gene level. IGF-I treatment
resulted in increases in both the protein and mRNA levels of HIF-1a, whereas IGF-II had no effect on its expression.
However, all of these stimuli exploited the PI-3K pathway.
CONCLUSION: IL-1b upregulated the levels of HIF-1a protein post-transcriptionally, whereas IGF-I increased HIF-1a at
the transcript level. In contrast, IGF-II did not affect the protein or gene expression levels of HIF-1a. Furthermore, all
of the tested stimuli exploited the PI-3K pathway to some degree. Based on these findings, we are able to suggest
that Hypoxia inducible Factor-1 exhibits protective activity in chondrocytes during osteoarthritis.
KEYWORDS: HIF-1a; Chondrocytes; Phosphatidylinositol-3-kinase (PI-3K), Cytokines; IL-1b; Growth factors; IGF-I,
IGF-II, Osteoarthritis; Articular cartilage.
Sartori-Cintra AR, Mara CS, Argolo DL, Coimbra IB. Regulation of hypoxia-inducible factor-1a (HIF-1a) expression by interleukin-1b (IL-1b), insulin-like
growth factors I (IGF-I) and II (IGF-II) in human osteoarthritic chondrocytes. Clinics. 2012;67(1):35-40.
Received for publication on August 5, 2011; First review completed on September 14, 2011; Accepted for publication on September 14, 2011
E-mail: gelsart@yahoo.com
Tel.: 55 19 3521-9587
INTRODUCTION
Articular cartilage is a highly specialized tissue present in
all diarthrodial joints, and its breakdown is a crucial event
in the etiopathogenesis of osteoarthritis (OA). OA is
characterized by the degeneration of articular cartilage in
association with subchondral bone erosions and sclerosis.
Numerous inflammatory cytokines, such as interleukins 1
and 6 (IL-1 and IL-6) and tumor necrosis factor-a (TNFa),
participate in the pathogenesis of this disease, increasing the
expression of proteolytic enzymes and metalloproteases
(MMPs) and accelerating the destruction of cartilage (1-3).
Chondrocytes are cartilage cells that exist in a hypoxic
microenvironment because cartilage is an avascular tissue.
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor
that activates the expression of target genes involved in
essential pathways regulating cellular survival under con-
ditions of hypoxia, such as angiogenesis and glycolysis (4).
Under normal oxygen tension, the HIF-1a subunit is marked
for ubiquitination and rapid proteosome-mediated degra-
dation by the von Hippel-Lindau tumor suppressor (pVHL).
During hypoxia, ubiquitination and degradation are inhib-
ited, increasing the steady-state level of HIF-1a protein in
the cytoplasm. HIF-1a subsequently translocates to the
nucleus, where it dimerizes with HIF-1b, the constitutively
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35expressed HIF-1 subunit, forming the transcription complex
HIF-1 (5,6). In addition to hypoxia, HIF-1a expression can be
induced by numerous other factors, including inflammatory
cytokines, reactive oxygen species (ROS), nitric oxide, and
hormone-like growth factors, such as Insulin-like growth
factor (IGF) and TGF-b (Transforming Growth-factor b) (7).
In previous studies, we identified expression of HIF-1a
associated with human OA as well as in normal chondro-
cytes under normal oxygen tension conditions and found
that HIF-1a protein levels were increased by TNFa treat-
ment (8). Because HIF-1a is related to cellular survival via
the modulation of genes related to this function, we believe
that when this transcription factor is present in osteoar-
thritic chondrocytes, it could be related to cytokine
modulation. Specifically, HIF-1a may modulate IL-1b,a
major catabolic factor involved in OA that can induce potent
changes in cartilage metabolism in OA joints, thereby
inhibiting the synthesis of cartilage-specific collagen II and
proteoglycans and increasing the production of numerous
MMPs (2,3,9).
Similarly, we chose to investigate insulin-like growth
factors I and II, which are reported to be involved in HIF-1a
regulation in other cell lines (10,11). In chondrocytes, the
anabolic role of these growth factors, especially IGF-I, is
well recognized as stimulating cellular proliferation and
extracellular-matrix synthesis (12,13). However, no studies
have examined whether IGF-I and II regulate the expression
of HIF-1a in these cells. Thus, the aim of the present study
was twofold (1): to investigate the modulation of the
expression of HIF-1a in human OA chondrocytes under
normal oxygen conditions in response to treatment with IL-
1b, IGF-I and IGF-II; and (2). to determine whether the
phosphatidylinositol-3-kinase (PI-3K) pathway participates
in this modulation, as is the case in other cell types.
MATERIALS AND METHODS
Isolation and culture of human OA chondrocytes
Human chondrocytes were obtained from patients with
OA who underwent knee joint replacement surgery at the
University Hospital of Campinas, Sa ˜o Paulo, Brazil. This
study was analyzed and approved by the local ethics
committee. The patients signed informed consent docu-
ments to allow the authors to use material from their
replaced joints in the current study. Approximately 80% of
the patients presented as class IV in the Kelgreen and
Lawrence (14). radiographical scale. Chondrocytes were
isolated from all remaining cartilage tissue as previously
described (15). Briefly, the cartilage was minced and
incubated in Hanks’ medium containing trypsin and
bacterial collagenase (2 mg/ml each) for 1 h at 37˚C. The
medium was subsequently discarded, and tissue frag-
ments were incubated overnight at 37˚Ci nD u l b e c c o ’ s
minimum essential medium (DMEM) containing 10% fetal
bovine serum and 0.5 mg/ml bacterial collagenase. The
released cells were filtered through a 70-mmn y l o nc e l l
strainer, were collected by centrifugation at 2506gf o r
5 min and were washed with collagenase-free medium.
Isolated chondrocytes were immediately frozen in freezing
media (90% FBS, 10% DMSO) and stored for future
experiments. For these experiments, cells were thawed
and plated in suspension cultures in 6-well ultralow
attachment plates (Corning, Acton, MA) at a density of
5610
6/ml. The cells were allowed to recover for 48 h in
DMEM containing 10% FBS, 2 mM glutamine, 1% vitamin
supplements, 100 U/ml penicillin and 100 mg/ml strepto-
mycin. Amphotericin B and ascorbic acid were avoided
because they can interfere with HIF-1a expression (16). For
experiments under normoxic conditions, cells were main-
tained at 37˚Ci n5 %C O 2 and 95% air (21% O2). The cells
were stimulated for 6 h with 10 ng/ml IL-1b Pierce
Endogen (N. Meridian Road, Rockford, IIL). To study PI-
3K, the specific inhibitor LY 294002 Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MO) was employed at a concentration
of 10 mM/ml. For treatment with IGF-I or IGF-II (at 10 ng/
ml each), cells were serum-depleted to 0.1% FBS 12 h
before the indicated treatment, and nuclear protein
extraction was performed 12 h after addition of the growth
factor.
Preparation of nuclear extracts
Nuclear extracts were isolated from the chondrocytes
according to the method of Dignam et al (17). using the
CellLytic NuCLEAR extraction kit (Sigma-Aldrich, St. Louis,
MO) at 4˚C to avoid nuclear protein denaturation according to
the manufacturer’s instructions. All buffers contained a
protease inhibitor cocktail with 2 mM 4-(2-aminoethyl) benze-
nesulfonylfluoride, 1.4 pMtrans-epoxysuccinyl-L-leucylamido
(4-guanidinobutane), 130 pM bestatin, 1 mM leupeptin, 0.3 pM
aprotinin (Sigma-Aldrich) and 2.6 mM calpain inhibitor
(Calbiochem, San Diego CA). The obtained protein concentra-
t i o n sw e r ea n a l y z e dv i at h eB r a d f o r dm e t h o da taw a v e l e n g t h
of 595 nm using a spectrophotometer.
Western Blot Analysis
For western blot analysis, 30 mg of nuclear chondrocyte
extract in 2x SDS buffer and distilled water (final volume of
30 ml) was denaturedat 95˚C for 90 sec and then separated on
an 8% SDS-polyacrylamide gel. Following electrophoresis,
the proteins were transferred to Hybond-P membranes
(Amersham Pharmacia Biotech) in buffer containing 20 mM
Tris HCl, 150 mM glycine and 20% methanol at 40 V for 18 h
at 4˚C. The membranes were blocked with Tris-Buffered
Saline (TBS) wash solution containing 5% nonfat milk and
0.1% Tween 20 (TBSMT) for 2 h at pH 7.6. The membranes
were incubated with the primary antibody, a mouse
monoclonal anti-HIF-1 antibody (1/250 dilution, Trans-
duction Laboratories, Lexington, KY), with shaking over-
night at 4˚C followed by incubation with the secondary
antibody, a rabbit anti-mouse IgG-horseradish peroxidase
conjugate (1/2,000 dilution, Amersham Pharmacia Biotech).
The membranes were washed three times (1615 min and
2610 min) between antibody incubations with TBMST, and
the blots were developed using an ECL detection kit
(Amersham Pharmacia Biotech). The membranes were
subjected to stripping and re-probed with a mouse mono-
clonal anti-b-actin antibody to normalize the results. The
bands were analyzed by densitometry and normalized using
ImageMaster TotalLab v.2.0 software (Amersham).
RNA Isolation and Real-Time PCR (qRT-PCR) Analysis
Total RNA was isolated from the cells using the TRIzol
reagent (Invitrogen) according to the manufacturer’s speci-
fications. The obtained RNA sample quality was evaluated
by gel electrophoresis. First-strand cDNA was generated
using Superscript II reverse transcriptase and oligo-dT as a
primer (Invitrogen). The mRNA expression levels of HIF-1a
and b-actin were obtained via relative gene expression
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36analysis using real-time-PCR (Applied Biosystems 7500 Real
Time PCR). Amplification of specific PCR products was
detected using SYBR Green PCR Master Mix (Applied
Biosystems). All primers employed in these experiments
were designed using VectorH3.0 software and prepared by
Invitrogen (Sa ˜o Paulo, Brazil). The primers used were as
follows: HIF-1a, forward 59 CTGACCCTGCACTCAATCAA
39, reverse 59 CTTTGCTTCTGTGTCTTCAGCAGCA 39; b-
actin, 59 GCTCGTCGTCGACAA CGGCTC 39, reverse 59
CAAACATGATCTGGGTCATCTTCTC 39.
The samples for qRT-PCR were prepared and analyzed in
triplicate in a reaction volume of 10 mL containing 5 mLo f
SYBR Green PCR Master Mix, 3 ml of cDNA from each
sample asa template (between10 and18 ngof cDNA),2 mlo f
primer solution (forward and reverse) and DEPC water. The
primer and cDNA concentrations were standardized. A
melting curve analysis was performed to confirm the
specificity of the amplification and the absence of primer
dimers. Samples were heated for 10 min at 95˚Ca n d
amplified for 50 cycles of 15 sec at 95˚C and 60 sec at 60˚C.
Blank controls were run in parallel to determine the
amplification efficiency within each experiment. Quanti-
fication was performed using a standard curve. Serial
dilutions of cDNA in dH2O, which were used as a calibrator,
were amplified to construct standard curves for target and
control genes. The slopes of the standard curves ranged from
-3.2 to -3.9. For each sample, the levels of the target and
control genes were determined based on the appropriate
standardcurve. The targetlevelwassubsequentlydivided by
the control gene level to obtain a normalized target value,
which was calibrated using the standard RNA sample.
Statistical Analysis
The results of three separate experiments were expressed
as means ¡ standard deviations. Data were analyzed using
nonparametric statistical analysis with the Kruskal-Wallis
test, and in the significant cases, the Duncan test was
applied to further discriminate group differences. For all
analyses, a p-value of ,0.05 was considered to be
significant.
RESULTS
IL-1b
Treatment with IL-1b downregulated HIF-1a gene expres-
sion in OA chondrocytes, although the difference was not
statistically significant. In contrast, when OA chondrocytes
were incubated with both IL-1b and LY2 94002 (a PI-3K
inhibitor), the observed inhibition was significantly more
intense and was statistically different from the control
(*p,0.05) (Fig. 1A). In contrast to the mRNA levels of HIF-
1a, the expression of HIF-1a protein assayed in nuclear
extracts was upregulated in OA chondrocytes stimulated
with IL-1b (*p,0.05). When LY 294002 treatment was
applied, we observed that there was a decrease in this
effect of IL-1b, with HIF-1a protein levels exhibiting
downregulation (*p,0.05) (Fig. 1B).
IGF-I
When the cells were treated with IGF-I, HIF-1a gene
expression was upregulated, whereas the application of
both IGF-I and LY294002 caused a significant reduction in
HIF-1a levels compared to control, untreated cells (*p,0.05).
These results suggest that IGF-I stimulation of HIF-1a
expression is largely mediated by the PI-3K pathway
(Fig. 2A). In addition to the upregulation of HIF-1a
mRNA by IGF-I, treatment with this growth factor also
significantly increased HIF-1a protein levels. The combina-
tion of IGF-I and LY294002 resulted in a complete
abrogation of the stimulatory effect and provoked a notable
Figure 1 - HIF-1a mRNA expression and protein levels in human chondrocytes treated with IL-1b. A) IL-1b decreases HIF-1a mRNA
expression in human chondrocytes cultured under normal oxygen conditions, and the combination of IL-1b and LY294002
downregulated HIF-1a mRNA even further (*p,0.05). B) Upregulation of HIF-1a protein levels was observed under treatment with IL-1b
(*p,0.05), which was largely abolished by LY294002 treatment, suggesting that this upregulation occurs, at least in part, through the
PI-3K pathway. This graph depicts the results normalized to endogenous b-actin protein levels.
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37decrease in HIF-1a nuclear protein levels compared to basal
levels (*p,0.05) (Fig. 2B).
IGF-II
Surprisingly, we did not observe upregulation of HIF-1a
mRNA expression when the cells were treated with IGF-II.
However, the results further showed that the PI-3K path-
way is involved in the basal regulation of HIF-1a gene
expression. The involvement of the PI-3K pathway is
reinforced by the finding that in cells treated with both
IGF-II and LY209002, the protein levels were significantly
reduced and were statistically different (*p,0.05) from
levels in the control, as well as from the levels in IGF-II-
treated cells (Fig. 3A). Unlike the previously demonstrated
upregulation of HIF-1a protein levels by IL-1b and IGF-I,
IGF-II failed to increase the expression of this protein. In
contrast, IGF-II downregulated HIF-1a protein levels.
However, this result corroborates the findings from the
Figure 2 - HIF-1a mRNA expression and protein levels in human chondrocytes treated with IGF-I. A) IGF-I increases the mRNA expression
of HIF-1a, and the combination of LY294002 and IGF-I produces downregulation of HIF-1a mRNA to subbasal levels (*p,0.05). B) HIF-1a
protein levels were increased by IGF-I treatment, and addition of LY294002 (a PI-3K pathway inhibitor) resulted in downregulation of
HIF-1a protein expression (*p,0.05) to reduced levels compared to controls. The results were normalized to the endogenous protein
b-actin.
Figure 3 - HIF-1a mRNA expression and protein levels in human chondrocytes treated with IGF-II. A) Unlike IGF-I, when IGF-II treatment
was applied, the mRNA expression of HIF-1a was decreased, and this downregulation was enhanced (*p,0.05) when IGF-II and
LY294002 were applied together. Inhibition of PI-3K by LY294002 caused downregulation of HIF-1a mRNA to reduced levels compared
to those of the controls. B) However, HIF-1a protein expression was also decreased by IGF-II treatment. This growth factor is regulated
by the PI-3K pathway, as well, because inhibition of this pathway by LY294002 decreased the expression of HIF-1a (*p,0.05). The
results were normalized to endogenous b-actin.
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38RNA expression analysis of HIF-1a following treatment of
the chondrocytes with IGF-II. Nevertheless, blocking the
PI-3K pathway further decreased HIF-1a to sub-basal levels
(*p,0.05) (Fig. 3B).
DISCUSSION
HIF-1a, a heterodimer transcription factor, plays a pivotal
role in articular cartilage development and viability (18,19);
however, its participation in the process of cartilage break-
down remains unclear. In this study, we observed that IL-1b
treatment downregulated HIF-1a mRNA expression in
human OA chondrocytes, though the difference was not
statistically significant. However, when the cells were treated
with the combination of IL-1b and LY 294002 (PI-3K pathway
inhibitor), we observed stronger, statistically significant
downregulation of HIF-1a mRNA expression. We found
evidence of differential regulation of HIF-1a protein levels
and mRNA expression. IL-1b increased HIF-1a levels
through the PI-3K pathway, as IL-1b-specific upregulation
was suppressed by blocking the PI-3K pathway. These
findings reinforce previous observations (20-23). in other cell
lines in which the regulation of HIF-1a by IL-1b occurs post-
transcriptionally. In further agreement with our results, other
investigators (24). who have performed real-time PCR
analyses using different cartilage samples (degenerated and
non-degenerated) have detected upregulation of HIF-1a,
mostly in degenerated areas, suggesting that this factor could
be related to a pathogenic mechanism involved in OA. As
observed in the current investigation, other researchers have
not found a significant effect of IL-1b treatment on mRNA
levels. In contrast with our results, this effect has not
previously been detected in cultured cells under normal
oxygen tension. These discrepancies can be explained by the
fact that other investigators have used chondrocyte mono-
layer cultures, whereas we used suspension cultures. We
previously demonstrated that HIF-1a was not present in OA
chondrocytes in monolayer culture systems (8).
Nevertheless, when other investigators have analyzed
the effect of IL-1b on chondrocytes cultured under
hypoxic conditions, they have also observed this increase.
Additionally, the same group (25). recently reported finding
elevated HIF-1a protein levels in human OA chondrocytes
cultured under conditions of hypoxia and normoxia when
they treated cells with IL-1b for an extended period (24 h),
suggesting a delayed response in OA chondrocytes, even
in cells cultured in a monolayer. Therefore, our findings
suggested that in chondrocytes, as in other cell lines, IL-1b
acts as a positive regulator of HIF-1a protein levels at the
post-transcriptional level. Our data also confirm that the
regulation of HIF-1a by IL-1b relies, at least in part, on the
PI-3K pathway, given that cells treated with inhibitors of
this pathway showed no effects of this cytokine. This post-
transcriptional regulation may suggest that HIF-1a has a
protective role because elevated protein levels may increase
the possibility of the binding of DNA to HIF-1 and the
subsequent transcription of genes related to cell survival.
In osteoarthritis, IGF-I expression is associated with
increasing synthesis of matrix molecules in early stages of
the disease and with osteophyte formation later. The lack of
an IGF-I pathway could be implicated in cartilage degen-
eration (3,26). In this study, we demonstrated increases in
HIF-1a mRNA expression and protein levels in IGF-I-
treated OA chondrocytes. The PI-3K pathway was the
preferred mechanistic route for this upregulation because
when this pathway was blocked, HIF-1a upregulation was
not observed. Moreover, without PI-3K, HIF-1a mRNA and
protein levels decreased to sub-basal levels, suggesting that
this pathway may be active even under baseline conditions.
This upregulation has also been observed in other cell lines
(27,28). Our findings suggested that IGF-I induces HIF-a
expression, although additional studies will be essential to
obtain a comprehensive understanding of the mechanisms
involved in this induction. IGF-1 treatment increases the
expression of HIF-1a at both the gene and protein levels,
which reinforces its protective activity of HIF-1a because
this growth factor is related to the maintenance of cartilage
homeostasis.
Previous studies have shown that IGF-II promotes
placental growth and function, and this process appears
to be related to the regulation of HIF-1 and HIF-2a (29-31).
To the best of our knowledge, this study is the first
investigation that verifies the action of IGF-II on HIF-1a
expression in human OA chondrocytes. Our results
regarding HIF-1a protein levels are similar to previous
observations made in murine throphoblast cells (29), but
our findings diverge from observations in several other
cell lines (27,30,31). We strongly suspect that these
differences can be accounted for by length of treatment
employed, given that our treatments were performed for
12 hours under low-serum conditions (0.1% FBS). In
contrast, other investigators have used cells treated with-
out serum deprivation with higher concentrations of IGF-II
for a more extended period of time (30,31), and they did
not use primary human OA chondrocytes. Our results may
suggest that in human OA chondrocytes, IGF-II and IGF-I
may play different roles; however, more studies are
necessary to confirm this hypothesis. We also cannot
discard the hypothesis that IGF-II may exert distinct effects
in human OA chondrocytes across different stages of the
disease because during our experiments, we treated cells
from patients in different phases of OA. This possibility
may bias our results. Interestingly, although we did not
see any significant effect of IGF-II on HIF-1a mRNA or
protein levels in human OA chondrocytes, blocking the PI-
3K pathway produced a statistically significant down-
regulation of HIF-1a mRNA and protein levels. This
finding suggests that expression of HIF-1a under normal
O2 levels in OA chondrocytes may also occur via this
pathway (31).
In conclusion, we observed that IL-1b post-transcription-
ally upregulated HIF-1a protein levels in human OA
chondrocytes. We also found that IGF-I upregulated HIF-
1a protein and mRNA levels, indicating that this action
occurs at the gene level (no effect of IGF-II on HIF-1a
regulation was observed). We have demonstrated that both
IL-1, the main catabolic agent, and IGF-1, an anabolic agent,
are able to stabilize HIF-1a under normal oxygen conditions
via the PI-3K pathway. These findings strongly suggest
that Hypoxia inducible Factor-1 has a protective role in
chondrocytes during osteoarthritis, and further studies are
needed to clarify this relationship.
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